目的观察前列地尔对肝酶异常重症患者肝功能的影响。方法急诊ICU肝酶异常患者92例随机均分为两组:对照组予以原发病及保肝治疗;治疗组加用前列地尔10μg静脉泵入,每日2次,疗程为8d。比较两组疗效和不良反应。结果治疗后,两组肝酶指标ALT、AST、TBil和DBil均较治疗前好转(P<0.05),治疗组的改善更明显(P<0.05)。治疗组总有效率高于对照组(93.48%vs.76.09%)(P<0.05)。治疗组用药期间未出现前列地尔相关的不良反应。结论在常规治疗的基础上早期加用前列地尔能有效改善肝酶学异常重症患者的肝功能。 Objective To observe the effect of alprostadil on liver function in severe patients with abnormal liver enzymes. Methods Ninety-two patients with abnormal ICU liver enzyme abnormalities were randomly divided into two groups: the control group was treated with primary disease and liver protection; the treatment group was treated with 10 μg of alprostadil intravenously twice daily for 8 days. The efficacy and adverse reactions of the two groups were compared. Results After treatment, the levels of ALT, AST, TBil and DBil in both groups were improved compared with before treatment (P <0.05), and the improvement in the treatment group was more obvious (P <0.05). The total effective rate of the treatment group was higher than that of the control group (93.48% vs.76.09%) (P <0.05). There were no alprostadil-related adverse effects during treatment in the treatment group. Conclusions The early application of alprostadil on the basis of routine treatment can effectively improve the liver function in patients with severe liver dysfunction.